Citations

Clear

9383 citation(s) found for "Thomas, PS".

HSR26-214: Impact of Upper Gastrointestinal Bleeding on Mortality and Healthcare Utilization in Gastric Cancer Patients: A Real-World Evidence Analysis from the 2021 NIS Dataset
Maniar, Pranay, Dave, Bhoomi, Gunasignhe, Maduka, Rocchetti, Jenna, Thomas, Beje , Dave, Bhoomi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 27, 2026 | Volume: 24 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2025.7387 | PMID 41991110 Get It

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes
Khurana, Arushi , Hayashi, Hikaru, Thach, Bethany J., Yang, Zhi Zhang, Negaard, Brianna J., Cerhan, James R., Novak, Anne J. , Habermann, Thomas M., Feldman, Andrew L., Parikh, S., Slager, Susan L., Ansell, Stephen M., Maurer, Matthew J., Faustman, D L, Habermann, Thomas M. , Cerhan, James R. , Cerhan, James R , Habermann, Thomas , Slager, Susan L , Ansell, Stephen M , Maurer, Matthew , Novak, Anne J , Hayashi, Hikaru, Gysbers, Brianna J. , Link, Brian K. , Feldman, Andrew L. , Parikh, Sameer A. , Slager, Susan L. , Ansell, Stephen M. , Maurer, Matthew J.

Mayo Clinic

American Journal of Hematology | March 27, 2026 | Volume: 101 | Issue: 6 | Pages: 1388-1397

10.1002/ajh.70293 | PMID 41891328 Get It

ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth. We evaluated sTNFR2 as a prognostic biomarker for overall survival (OS) in newly diagnosed lymphoma using a prospective cohort study with banked pretreatment serum samples. sTNFR2 was higher in 1513 lymphoma patients compared to 499 age and sex matched controls ( p < 0.0001). Using Kaplan–Meier curves and Cox proportional hazards models to estimate hazard ratios [HR] (high vs. low tertile), higher levels of sTNFR2 at diagnosis were associated with inferior OS across all seven major lymphoma subtypes: Hodgkin lymphoma ( p < 0.0001; HR = 12.6), diffuse large B‐cell lymphoma ( p < 0.0001; HR = 2.6), follicular lymphoma ( p = 0.00017; HR = 2.5), mantle cell lymphoma ( p < 0.0001; HR = 4.2), small lymphocytic lymphoma ( p = 0.012; HR = 2.4), marginal zone lymphoma ( p = 0.0012; HR = 3.1), and T‐cell lymphoma ( p < 0.0001; HR = 3.1). Using CITE‐seq profiling of tumor microenvironment tissue, we sought to identify cellular source(s) of circulating sTNFR2. In tumor tissue from follicular lymphoma, high TNFR2‐expressing cells were found to be T‐regulatory (Treg) cells, suggestive of a Treg‐driven cancer. In tissue from a case of marginal zone lymphoma, high TNFR2 expression was found on CD4+ and CD8+ T cells, B cells, and monocytes but also directly on tumor cells. We conclude sTNRF2 is a strong prognostic biomarker of OS across major lymphoma subtypes and may be useful to guide therapeutic choices, including targeted therapies against immunosuppressive TNFR2‐expressing Tregs.
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
Besse, Benjamin, Subbiah, Vivek, Curigliano, G., Bowles, Daniel W. , Doebele, Robert C. , Mansfield, Aaron S. , Baik, Christina S. , Lopes, Gilberto , Paz-Ares, Luis , Taylor, Matthew H. , Tan, Daniel S.W., Alonso, G. , Gadgeel, Shirish M., Kalemkerian, Gregory P. , Ou, S.-H.I., Wekken, Anthonie J. van der , Becerra, Carlos R., Evangelist, Makenzi Colleen, Griesinger, Frank, Lou, Yanyan , Mazières, Julien, Melear, Jason M., Narang, Mohit , Saxena, Ashish, Thomas, Michael, Thomassen, Amber , Lee, Dae Ho, Kim, Dong-Wan, Gainor, Justin F., Subbiah, Vivek , Besse, Benjamin , Besse, Benjamin , Subbiah, Vivek , Curigliano, Giuseppe , Tan, Daniel S W , Gadgeel, Shirish , Ou, Sai-Hong I , van der Wekken, Anthonie J , Liu, Stephen V , Lou, Yanyan , Mazières, Julien , Melear, Jason M , Narang, Mohit , Thomas, Michael , Lee, Dae Ho , Kim, Dong-Wan , Gainor, Justin F , Mansfield, Aaron S , Bowles, Daniel W , Curigliano, Giuseppe , Paz‐Ares, Luis , Gadgeel, Shirish M. , Griesinger, Frank , Liu, Stephen V. , Saxena, Ashish , Thomas, Michael , Wang, Sophia Y. , Kim, Dong‐Wan , Gainor, Justin F. , Taylor, Matthew H.

Mayo Clinic

Journal of Clinical Oncology | March 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1190-1197

10.1200/jco-25-01489 | PMID 41886723 Get It

RET fusions appear in 1%-2% of non–small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385 ) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET -altered NSCLC and RET fusion–positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion–positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion–positive NSCLCs, confirming previous findings with longer follow-up.
Thirty-Six-Month Multicentre Outcomes of Combined Phacoemulsification and Hydrus Microstent Implantation in Eyes With Normal Tension Glaucoma
Ang, Bryan Chin Hou, Sim, Jackie Jia Lin , Chua, Chun Hau, Khairy, Thomas, Salimi, Ali , Harasymowycz, Paul , Ang, Bryan Chin Hou , Ang, Bryan C H , Salimi, Ali , Betzler, Bjorn Kaijun , Ramanathan, Rajesh, Hong, Ashley Shuen Ying

Mayo Clinic

Journal of Glaucoma | March 26, 2026 | Volume: 35 | Issue: 6 | Pages: 369-376

10.1097/ijg.0000000000002709 | PMID 41934671 Get It

Precis: This retrospective multicentre study of 77 NTG eyes undergoing phacoemulsification and Hydrus implantation showed a sustained reduction in medication burden, while maintaining IOP levels. Complications were rare and nonsight-threatening. Purpose: To evaluate 36-month outcomes of combined phacoemulsification and Hydrus Microstent implantation (Phaco-Hydrus) in eyes with normal tension glaucoma (NTG). Methods: This multicentre retrospective study included 77 NTG eyes from Singapore and Canada that underwent Phaco-Hydrus between 2014 and 2023. Primary outcomes were changes in intraocular pressure (IOP) and medication burden, and cumulative success probabilities from Kaplan-Meier (KM) analyses. Longitudinal changes were analysed using generalized estimating equations. Results: Of 77 eyes, 31 completed 36 months of follow-up. Mean baseline IOP and medications was 13.5±2.5 mm Hg and 1.7±0.9, respectively. No significant reductions in IOP were observed. A sustained reduction in medication use was observed at all follow-up timepoints ( P ≤0.001). At 36 months, medication use decreased by −0.7±0.2 [adjusted mean difference±SE of the mean [SEM]]. Proportion of medication-free eyes increased from 7.8% (n=6/77) at baseline to 45.2% (n=14/31) at 36 months. Cumulative success probabilities varied widely based on definitions. When defined as a decrease in ≥1 medication from baseline without an increase in IOP, or IOP ≤15 mm Hg and reduced ≥20% from baseline while medication-free, and no additional laser or incisional glaucoma surgery, this was 40.7% at 36 months. No visual field mean deviation progression was detected. Adverse events were infrequent and nonsight-threatening. Conclusion: In eyes with NTG, Phaco-Hydrus may offer a greater role in medication reduction or achieving a medication-free status over 36 months, rather than absolute IOP reduction.
Empowering Neurosurgical Leadership: Training the Next Generation of Neurosurgical Leaders
Razak, Shahaan S. , Veeravagu, Anand , Stiehl, Emily, Sharan, Ashwini , Levy, Elad, Khalessi, A, Kalkanis, Steven N. , Asmussen, Brian, Langer, David, Chambless, Lola B. , Hilgart, Michele, Ratliff, John K. , Scarrow, Alan M., Scarrow, Alan, Ratliff, John , Stiehl, Emily , Khalessi, Alexander A., Langer, David J., Haydu, Lauren E. , Air, Ellen L. , Nahed, Brian V.

Mayo Clinic

Neurosurgery | March 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000003996 | PMID 41885450 Get It

BACKGROUND AND OBJECTIVES: The Congress of Neurological Surgeons (CNS) Leadership Institute developed the first structured leadership program designed specifically for neurosurgeons. Led by the experts in neurosurgery, health care administration, and business, the program provides formal leadership training and mentorship aimed at advancing neurosurgeons' professional development at local, regional, national, and international levels. METHODS: The CNS Leadership Institute offers 2 curricula tailored for junior and senior faculty. Training begins with assigned readings, webinars, and online lectures that establish essential leadership principles. Core learning occurs during 2 in-person courses featuring interactive lectures, feedback sessions, and a longitudinal leadership project guided by national mentors. Program outcomes were assessed through a 40-question survey of alumni evaluating training effectiveness, skill application, and career advancement. RESULTS: Since 2016, 195 neurosurgeons have completed the CNS Leadership Institute. Among the 77 survey respondents, 70.1% reported significant professional advancement (new leadership role or job transition), and 64.8% directly attributed their advancement in skills and insights acquired through the program. Overall program effectiveness was rated 4.4 of 5, and the mean likelihood-to-recommend was 8.95 (95% CI: 8.70-9.20), yielding a Net Promoter Score of +63 (95% CI: +49 to +77). Alumni have assumed prominent roles including 16 Residency Program Directors, 3 Department Chairs, 1 Vice Dean, 4 Service Line Leaders, 13 CNS Executive Committee members, and over 100 committee or editorial board appointments critical to the specialty. CONCLUSION: The CNS Leadership Institute equips neurosurgeons with structured leadership training, mentorship, and practical tools to enhance their effectiveness as leaders. Survey results confirm that the program has a measurable impact on participants' career trajectories and professional growth. This initiative provides a reproducible model for cultivating the next generation of neurosurgical leaders and advancing the specialty's capacity for strategic, transformational leadership.
Mechanical dyssynchrony and septal–lateral perfusion heterogeneity predict adverse left ventricular remodelling beyond ECG-defined LBBB
Brandão, Simone Cristina Soares, Joseph, Lee , Brown, Jenifer M. , Lopez, Diana, Lemley, M A R K, Ramirez, Giselle, Kavanagh, P A U L, Kriekinge, Serge D. Van , Builoff, Valerie , Divakaran, Sanjay, Weber, Brittany, Hainer, Jon, Carre, Sylvain , Blankstein, Ron, Dorbala, Sharmila, Le, Viet T, Mason, Steve, Chareonthaitawee, Panithaya, Wopperer, Samuel, Rosamond, Thomas, Berman, D., Dey, Damini, Carli, Marcelo F Di, Slomka, Piotr J, Huck, Daniel M, Soares Brandão, Simone Cristina , Kavanagh, Paul , Divakaran, Sanjay , Weber, Brittany , Hainer, Jon , Blankstein, Ron , Dey, Damini , Di Carli, Marcelo F , Huck, Daniel , Brown, Jenifer Michelle , Lopez, Diana, Lemley, Mark , Kavanagh, Paul , Liang, Joanna, Dorbala, Sharmila , Le, Viet T. , Mason, Steve, Knight, Stacey , Chareonthaitawee, Panithaya , Wopperer, Samuel, Berman, Daniel S. , Dey, Damini , Carli, Marcelo F. Di , Slomka, Piotr J

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | March 26, 2026 | Volume: 27 | Issue: 6 | Pages: 1255-1265

10.1093/ehjci/jeag081 | PMID 41902398 Get It

Abstract Aims Left bundle branch block (LBBB) is associated with mechanical dyssynchrony, heterogeneous perfusion, and adverse left ventricular (LV) remodelling. However, not all patients with LBBB develop cardiomyopathy, and dyssynchrony can occur without conduction defects. The role of microvascular dysfunction remains uncertain. We aimed to assess how mechanical dyssynchrony and perfusion heterogeneity relate to LV remodelling and function in patients with and without LBBB. Methods and results We analysed 233 patients with LBBB and 932 matched controls who underwent PET myocardial perfusion imaging, assessing mechanical dyssynchrony (phase entropy), LV volumes, and ejection fraction (EF); coronary vascular resistance (CVR), myocardial blood flow (MBF), myocardial flow reserve (MFR) as markers of microvascular function; and septal-to-lateral MBF ratio (SLR) as a measure of regional perfusion heterogeneity. Compared with controls, LBBB patients had greater dyssynchrony (56% vs. 40%), larger LV volumes, and lower EF (54% vs. 67%) (all P &lt; 0.001), as well as higher stress CVR (37 vs. 34 mmHg/mL·min−1·g−1), and lower MBF (2.4 vs. 2.6 mL/min/g), MFR (2.4 vs. 2.6), and SLR (0.95 vs. 1.00) (all P &lt; 0.05). Among patients with dyssynchrony, SLR &lt;1.0 identified greater remodelling. In multivariable regression, phase entropy and SLR independently predicted LV volumes and EF, with adverse effects of SLR reduction amplified in LBBB (interaction P &lt; 0.01). In Cox analysis, phase entropy (HR:1.02, P = 0.01), MFR (HR:0.62, P &lt; 0.001), and LVEF (HR:0.97, P &lt; 0.001) were independently associated with death or heart failure hospitalization, whereas LBBB was not. Conclusion Mechanical dyssynchrony and perfusion heterogeneity independently predict adverse LV remodelling, irrespective of LBBB. Integrated imaging improves cardiomyopathy stratification.
Computed Tomography in Preoperative Planning of Minimally Invasive Valvular Heart Surgery: A Systematic Review of Mixed Evidence and Clinical Application
Bejand, Elnaz Azarmi, Suwita, Benedicta Mutiara , Akowuah, Enoch , Deshpande, Ranjit, Zacharias, Joseph , Iyengar, Srikanth, Bahrami, Toufan , Mirsadraee, Saeed , Mirsadraee, Saeed , Deshpande, Ranjit, Rajiah, Prabhakar

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | March 26, 2026 | Volume: 68 | Issue: 4 | Pages: No page available

10.1093/ejcts/ezag101 | PMID 41904670 Get It

Abstract Objectives Minimally invasive cardiac surgery (MICS) offers significant advantages over conventional sternotomy, including reduced trauma and faster recovery. Preoperative planning is crucial, with computed tomography (CT) emerging as an essential imaging tool. This systematic review aims to evaluate CT’s role in MICS planning, focusing on imaging protocols, surgical guidance, and patient outcomes. Methods This study included studies published between January 2003 and January 2025 that examined the role of CT imaging in planning minimally invasive valvular heart surgery. A comprehensive search was conducted in Medical Literature Analysis and Retrieval System Online (MEDLINE), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Excerpta Medica Database (EMBASE) using predefined keywords and medical subject headings (MeSH) terms related to CT imaging, angiography, minimally invasive surgery, robotic surgery, aortic valve surgery, and mitral valve surgery. Results Initial search found 378 studies, and 17 studies were included in the review. The studies highlight CT’s value in assessing surgical feasibility, vascular access, and risk stratification. CT aids in selecting arterial cannulation sites, guiding aortic occlusion strategies, and optimizing port placement. It also identifies contraindications, such as extensive atherosclerosis and anatomical abnormalities, that may necessitate sternotomy. Conclusions Current evidence underscores CT’s critical role in optimizing MICS planning and enhancing patient safety.
CT data harmonization via learned virtual monoenergetic imaging for cross‐kV scan translation and radiomics reproducibility
Chang, Shaojie , Swicklik, Joseph R., Zhou, Zhongxing, Kharat, Shravani, Wellinghoff, Jarod , Gong, Hao , Williamson, Eric E. , Foley, Thomas A. , McCollough, Cynthia H., Leng, Shuai, Gong, Hao , McCollough, Cynthia H. , Leng, Shuai

Mayo Clinic

Medical Physics | March 26, 2026 | Volume: 53 | Issue: 4 | Pages: No page available

10.1002/mp.70403 | PMID 41881591 Get It

Abstract Background Radiomics extracts quantitative imaging features from computed tomography (CT) data for clinical decision‐making. However, variations in acquisition parameters—particularly x‐ray tube voltage (kV)—introduce non‐biological variability in attenuation values, limiting the reproducibility of radiomic features across scanners, protocols, and institutions. Purpose To develop and evaluate a CT dAta harmoNiZAtion framework based on deep learNed vIrTual monoEnergetic imaging (TANZANITE), which leverages the keV flexibility of virtual monoenergetic images (VMIs) to enable cross‐kV scan translation and radiomics harmonization. Methods TANZANITE is a model hub consisting of multiple pre‐trained convolutional neural networks (CNNs), each designed to translate VMIs from 1 keV level to another. Phantom‐based calibration was first used to determine energy‐equivalent (Eff_E) keV levels corresponding to each tube potential (e.g., Eff_E(A) keV for source kV and Eff_E(B) keV for target kV). A CNN trained using 69 120 patches from seven patient cases to map VMIs from Eff_E(A) to Eff_E(B) was selected from the TANZANITE hub and applied directly to clinical CT images acquired at the source kV. This harmonized the images to match the attenuation characteristics of the target kV setting. Evaluation was conducted on independent dual‐energy CT datasets acquired at 100/Sn150 kV. Regions of interest (ROIs) were placed in the kidney, liver, and spine to assess CT number consistency and radiomic feature reproducibility. The concordance correlation coefficient (CCC) was calculated across 93 non‐shape radiomic features. Results After TANZANITE processing with 100 kV images, CT numbers in evaluated organs closely matched the Sn150 kV reference values in four testing patient cases. For example, mean kidney CT numbers changed from 320 HU (100 kV) to 156 HU (TANZANITE), approximating the Sn150 kV value of 160 HU. Similar changes were observed in the liver (157–105 HU vs. 104 HU reference) and spine (45–22 HU vs. 19 HU reference). Radiomic reproducibility improved substantially across organs: mean CCC increased from 0.590 to 0.995 in the liver, 0.300 to 0.970 in the kidney, and 0.630 to 0.968 in the spine. Post‐TANZANITE, over 98% of features exceeded the stability threshold (CCC ≥ 0.900) in all three representative organs. Conclusion TANZANITE provides a flexible, image‐domain harmonization framework by learning the keV‐to‐keV translation in the VMI domain and applying pre‐trained CNNs to clinical kV images. It improves CT number consistency and organ‐specific radiomic reproducibility without requiring raw projection data or scanner‐specific training. This approach supports consistent quantitative imaging across multiple‐kV acquisition protocols, enhancing radiomics reliability in clinical settings.
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Antonarakis, Emmanuel S., Cao, Qing , Catharine, Victoria , Carneiro, Benedito A. , Souza, André , VanderWeele, David James , Singh, Parminder, Bryce, Alan H. , Kelly, W. Kevin., Jha, Gautam , Lewis, Brian , Barata, P., Sartor, A. Oliver, Proudfoot, James A. , Davicioni, Elai, Dhawan, Mallika, Morgans, Alicia K., Ryan, Charles J. , Antonarakis, Emmanuel S. , Singh, Parminder , Antonarakis, Emmanuel S. , Antonarakis, Emmanuel S , De Souza, Andre L , VanderWeele, David J , Singh, Parminder , Kelly, W Kevin , Jha, Gautam G , Barata, Pedro , Sartor, A Oliver , Stadler, Walter M , Proudfoot, James A , Davicioni, Elai , Dhawan, Mallika , Morgans, Alicia K , Ryan, Charles J , Bryce, Alan H , Antonarakis, Emmanuel S , Barata, Pedro C. , Sartor, Oliver , Stadler, Walter M. , Davicioni, Elai , Dhawan, Mallika , Morgans, Alicia K. , Cao, Qing

Mayo Clinic

Clinical Cancer Research | March 25, 2026 | Volume: 32 | Issue: 12 | Pages: 2403-2412

10.1158/1078-0432.ccr-25-4823 | PMID 41880596 Get It

Abstract Purpose: This multicenter, single-arm, phase II trial evaluated the safety and efficacy of cabazitaxel and carboplatin followed by abiraterone, plus androgen deprivation therapy (ADT), in patients with high-volume metastatic castration-sensitive prostate cancer (mCSPC). Patients and Methods: Eligible patients had high-volume mCSPC and ≤3 months of prior ADT. Patients received six 21-day cycles of cabazitaxel (20 mg/m2) and carboplatin (AUC 4) with continuous ADT, followed by maintenance abiraterone (1,000 mg daily) and prednisone (5 mg daily). The primary endpoint was the proportion of patients free of prostate-specific antigen (PSA) or radiographic progression at 12 months. Secondary endpoints included complete PSA response (≤0.2 ng/mL), objective response, progression-free survival (PFS), and safety. Overall survival (OS) was also reported. Results: Sixty-one participants were enrolled at eight sites. The median age was 64 years, median baseline PSA was 6.6 ng/mL (0.07–745.7 ng/mL), 73.3% had Gleason grade group 5, 69.5% had 10 or more metastases, and 19.6% had a homologous recombination repair (HRR) mutation. PSA PFS at 12 months was 84.6% [95% confidence interval (CI), 72.5%–91.7%], and OS at 12 months was 94.8% (84.7%–98.3%). Complete PSA response was 66.7%, and complete objective response was 30.7%. Contrary to our hypothesis, relative to HRR wild-type patients, HRR-mutated patients (19.6%) had numerically fewer complete PSA responses (33.3% vs. 70.3%) and inferior PFS (HR, 2.43; 95% CI, 0.93–6.39). Common side effects of this quadruplet regimen included fatigue, nausea, and diarrhea. Conclusions: Cabazitaxel and carboplatin followed by abiraterone, together with ADT, were feasible, safe, and efficacious in patients with high-volume mCSPC and warrant further study in larger randomized trials.
The prevalence of Lewy body pathology across nine international community-based cohorts
Gibson, Lucy L. , Suemoto, Claudia K, Corrada, Maria M, Gómez-Isaza, Laura , Grinberg, Lea T, Kapasi, Alifiya , Jicha, Gregory A, Keene, C Dirk, Latimer, Caitlin S, Leite, Renata E P, Montine, Thomas, Neltner, Allison M. , Troncoso, Juan, Walker, Keenan A, Wang, Shih-Hsiu J, Aarsland, Dag, Nelson, Peter T, Suemoto, Cláudia Kimie , Suemoto, Claudia Kimie , Kapasi, Alifiya , Kovacs, Gabor G , Myllykangas, Liisa , Walker, Rod , Attems, Johannes , Abner, Erin L. , Corrada, María M. , Grinberg, Lea T. , Jicha, Gregory A. , Kawas, Claudia H. , Kovács, Gábor G. , Latimer, Caitlin S. , Leite, Renata Elaine Paraizo , Myllykangas, Liisa , Troncoso, Juan C. , Walker, Keenan A. , Aarsland, Dag , Nelson, Peter T.

Mayo Clinic

Brain | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag112 | PMID 41885166 Get It

Abstract Reported prevalence estimates of Lewy body pathology (LBP) vary widely, often without considering brain regional distributions or demographic influences. Large, population-representative autopsy cohorts are needed to provide estimates and clarify the distribution and clinical implications of LBP. Neuropathological, genetic, and clinical data were pooled from nine community- or population-based brain autopsy cohorts in the USA (n=6), Brazil, Austria, and Finland (n=7309 total; 59% women; mean age of death 84.2 years). Cognitive status was available for 6166 participants: dementia (38.5%), mild cognitive impairment (14.8%), and cognitively unimpaired (47.0%). Frequency of LBP was examined by anatomical distribution (neocortical, limbic, brainstem, amygdala, olfactory) and stratified by covariates. Prevalence was calculated in meta-analysis, and mixed-effect logistic regression examined associations with sex, cognitive status, Alzheimer’s disease neuropathological change (ADNC), and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) co-pathology. Overall, 27.3% of participants had LBP: neocortical 8.4%, limbic 6.8%, brainstem 4.8%, amygdala 3.7%, and olfactory 3.6%. Neocortical LBP was associated with dementia (present in 15%; OR=4.06 [95%CI 3.24-5.10]) and with increased odds of ADNC (OR=2.30 [95%CI 1.88–2.81]) and LATE-NC (OR=2.03 [95%CI 1.69-2.44]). Sex differences were not observed in the frequencies of neocortical or limbic LBP. However, amygdala-predominant LBP was more frequent in women (OR=1.53 [95%CI 1.06-2.21]) whereas brainstem-predominant LBP was more common in men (OR=0.64 [95%CI 0.49-0.84]). Additionally, amygdala-predominant LBP was associated with increased odds of comorbid ADNC (OR=12.7 [95%CI 5.30–30.6]) while brainstem-predominant LBP was not associated with greater odds of ADNC co-pathology (OR=0.88 [95%CI 0.67–1.16]). Pooling data from large, international community-based autopsy cohorts allows for more robust estimates of region-specific LBP prevalence and their associations with cognitive status. The observed sex- and co-pathology–specific differences in brainstem and amygdala-predominant LBP highlight potential biological heterogeneity and suggest that distinct disease pathways may underlie these patterns.